Shanghai-based ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (IMMUNEONCO-B) reported a further share repurchase on 7 July 2026, acquiring 91,800 H shares on the Hong Kong Stock Exchange under its existing mandate approved on 28 May 2026.

Key transaction details • Volume: 91,800 H shares • Price range: HKD 3.57–3.86 per share • Aggregate consideration: HKD 0.34 million

Capital structure post-transaction (7 July 2026) • Issued shares (excluding treasury): 418.81 million, down 0.02% from 418.90 million on 6 July 2026 • Treasury shares: 1.67 million, up from 1.58 million • Total issued shares (including treasury): unchanged at 420.48 million

Repurchase mandate utilisation • Authorised limit: 43.15 million shares • Cumulative shares repurchased to date: 1.67 million • Utilisation rate: 0.39% of the mandate

All repurchased shares have been retained as treasury stock; none have been cancelled. In accordance with Hong Kong listing rules, the company is restricted from issuing, selling or transferring treasury shares until 7 August 2026.